G129 | »ó¼¼ºÒ¸íÀÇ Ã´¼ö¼º ±ÙÀ§Ãà | Spinal muscular atrophy, unspecified |
 |
G13 | ´Þ¸® ºÐ·ùµÈ Áúȯ¿¡¼ÀÇ ÀÏÂ÷ÀûÀ¸·Î ÁßÃ߽Űæ°èÅë¿¡ ¿µÇâÀ» ÁÖ´Â °èÅ뼺 À§Ãà | Systemic atrophies primarily affecting central nervous system in diseases classified elsewhere |
 |
G130 | ½Å»ý¹°µþ¸² ½Å°æ±Ùº´Áõ ¹× ½Å°æº´Áõ | Paraneoplastic neuromyopathy and neuropathy |
 |
G130 | ¾ÏÁ¾¼º ½Å°æ±ÙÀ°º´Áõ | Carcinomatous neuromyopathy (C00-C97+) |
 |
G130 | °¨°¢¼º ½Å»ý¹°µþ¸² ½Å°æº´Áõ[µ¥´Ïºê¶ó¿î] | Sensorial paraneoplastic neuropathy [Denny Brown](C00-D48+) |
 |
G131 | ½Å»ý¹°Áúȯ¿¡¼ ÀÏÂ÷ÀûÀ¸·Î ÁßÃ߽Űæ°èÅëÀ» ħ¹üÇÏ´Â ±âŸ °èÅ뼺 À§Ãà | Other systemic atrophy primarily affecting central nervous system in neoplastic disease |
 |
G131 | ½Å»ý¹°µþ¸² º¯¿¬ºÎ³úº´Áõ | Paraneoplastic limbic encephalopathy (C00-D48+) |
 |
G132 | Á¡¾×ºÎÁ¾¿¡¼ ÀÏÂ÷ÀûÀ¸·Î ÁßÃ߽Űæ°èÅëÀ» ħ¹üÇÏ´Â °èÅ뼺 À§Ãà | Systemic atrophy primarily affecting central nervous system in myxoedema (E00.1+, E03.-+) |
 |
G138 | ´Þ¸® ºÐ·ùµÈ ±âŸ Áúȯ¿¡¼ ÀÏÂ÷ÀûÀ¸·Î ÁßÃ߽Űæ°èÅëÀ» ħ¹üÇÏ´Â °èÅëÀû À§Ãà | Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere |
 |
G14 | ¼Ò¾Æ¸¶ºñÈÄ ÁõÈıº | Postpolio syndrome |
 |
G14 | ¼Ò¾Æ¸¶ºñÈÄ Ã´¼ö¼º ÁõÈıº | Postpolio myelitic syndrome |
 |
G20 | ÆÄŲ½¼ º´ | Parkinson's disease |
 |
G20 | ¹ÝÆÄŲ½¼Áõ | Hemiparkinsonism |
 |
G20 | ¶³¸²¸¶ºñ | Paralysis agitans |
 |
G20 | ÆÄŲ½¼Áõ ¶Ç´Â ÆÄŲ½¼º´ NOS | Parkinsonism or Parkinson's disease NOS |
 |
G20 | Ư¹ß¼º ÆÄŲ½¼Áõ ¶Ç´Â ÆÄŲ½¼º´ | Idiopathic Parkinsonism or Parkinson's disease |
 |
G20 | ÀÏÂ÷¼º ÆÄŲ½¼Áõ ¶Ç´Â ÆÄŲ½¼º´ | Primary Parkinsonism or Parkinson's disease |
 |
G21 | ÀÌÂ÷¼º ÆÄŲ½¼Áõ | Secondary parkinsonism |
 |
G210 | ¾Ç¼º ½Å°æÀÌ¿ÏÁõÈıº | Malignant neuroleptic syndrome |
 |
G211 | ±âŸ ¾à¹°-À¯¹ß ÀÌÂ÷¼º ÆÄŲ½¼Áõ | Other drug-induced secondary parkinsonism |
 |